Research graph
References from Multidimensional efficacy characterization of xeligekimab in moderate-to-severe plaque psoriasis: regional responses, treatment targets, and patient-reported outcomes from a randomized controlled trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Psoriasis
10.1016/s0140-6736(20)32549-6 · 2021 · External reference
Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression
10.1111/jdv.14460 · 2017 · External reference
Effect of Ixekizumab on patient reported outcomes and quality of life in patients with moderate-to-severe plaque psoriasis: 5-year results from the UNCOVER-1 and -2 studies
10.36849/jdd.5821 · 2021 · External reference
Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies
10.1111/jdv.12106 · 2014 · External reference
Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management
10.1111/bjd.17128 · 2018 · External reference
Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis
10.4049/jimmunol.1800013 · 2018 · External reference
Bimekizumab versus Secukinumab in plaque psoriasis
10.1056/nejmoa2102383 · 2021 · External reference
Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis
10.1007/s13555-021-00511-1 · 2021 · External reference
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
10.1093/bjd/ljae062 · 2024 · External reference
Effectiveness of IL-23 inhibitor Guselkumab in real-world Chinese patients with psoriasis during a 20-week period
10.2147/ptt.s312109 · 2021 · External reference
Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents
10.35541/cjd.20220652 · 2023 · External reference
Defining on-treatment remission in plaque psoriasis: a consensus statement from the National Psoriasis Foundation
10.1001/jamadermatol.2025.1625 · 2025 · External reference
Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients
10.1111/bjd.17403 · 2019 · External reference
Variation of body regional responses to Ustekinumab and Secukinumab in psoriasis patients: a real-world retrospective study and literature review
10.1111/dth.15950 · 2022 · External reference
Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis
10.1177/0091270008329556 · 2009 · External reference
Secukinumab in plaque psoriasis--results of two phase 3 trials
10.1056/nejmoa1314258 · 2014 · External reference
Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis
10.1056/nejmoa1512711 · 2016 · External reference
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
10.1002/14651858.cd011535.pub4 · 2020 · External reference
Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis
10.1016/j.jdermsci.2020.06.003 · 2020 · External reference
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
10.1016/s0140-6736(21)00126-4 · 2021 · External reference
From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis
10.1016/j.jaad.2016.10.017 · 2017 · External reference
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
10.1016/s0140-6736(15)60125-8 · 2015 · External reference
Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis
10.1136/annrheumdis-2021-220865 · 2022 · External reference
Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis
10.1111/jdv.14951 · 2018 · External reference
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study
10.1016/j.jaad.2016.08.008 · 2017 · External reference
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
10.1111/jdv.14878 · 2018 · External reference
Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study
10.1016/j.jaad.2018.06.039 · 2019 · External reference
Efficacy and safety of Ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials
10.1007/s13555-020-00367-x · 2020 · External reference
The psychosocial burden of psoriasis
10.2165/00128071-200506060-00005 · 2005 · External reference
Clinical meaningfulness of complete skin clearance in psoriasis
10.1016/j.jaad.2016.03.026 · 2016 · External reference
Phase 3 studies comparing Brodalumab with Ustekinumab in psoriasis
10.1056/nejmoa1503824 · 2015 · External reference
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: results from 3 phase III psoriasis clinical trials
10.1016/j.jaad.2016.07.034 · 2016 · External reference
Research techniques made simple: murine models of human psoriasis
10.1016/j.jid.2017.10.013 · 2018 · External reference
Neuroimmune interactions in chronic itch of atopic dermatitis
10.1111/jdv.15973 · 2020 · External reference
Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA
10.1111/ced.12841 · 2016 · External reference
Defining on-treatment remission in plaque psoriasis: a consensus statement from the National Psoriasis Foundation
10.1001/jamadermatol.2025.1625 · ExternalCitation · doi-reference
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
10.1002/14651858.cd011535.pub4 · ExternalCitation · doi-reference
Efficacy and safety of Ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials
10.1007/s13555-020-00367-x · ExternalCitation · doi-reference
Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis
10.1007/s13555-021-00511-1 · ExternalCitation · doi-reference
Clinical meaningfulness of complete skin clearance in psoriasis
10.1016/j.jaad.2016.03.026 · ExternalCitation · doi-reference
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: results from 3 phase III psoriasis clinical trials
10.1016/j.jaad.2016.07.034 · ExternalCitation · doi-reference
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study
10.1016/j.jaad.2016.08.008 · ExternalCitation · doi-reference
From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis
10.1016/j.jaad.2016.10.017 · ExternalCitation · doi-reference
Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study
10.1016/j.jaad.2018.06.039 · ExternalCitation · doi-reference
Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis
10.1016/j.jdermsci.2020.06.003 · ExternalCitation · doi-reference
Research techniques made simple: murine models of human psoriasis
10.1016/j.jid.2017.10.013 · ExternalCitation · doi-reference
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
10.1016/s0140-6736(15)60125-8 · ExternalCitation · doi-reference
Psoriasis
10.1016/s0140-6736(20)32549-6 · ExternalCitation · doi-reference
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
10.1016/s0140-6736(21)00126-4 · ExternalCitation · doi-reference
Secukinumab in plaque psoriasis--results of two phase 3 trials
10.1056/nejmoa1314258 · ExternalCitation · doi-reference
Phase 3 studies comparing Brodalumab with Ustekinumab in psoriasis
10.1056/nejmoa1503824 · ExternalCitation · doi-reference
Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis
10.1056/nejmoa1512711 · ExternalCitation · doi-reference
Bimekizumab versus Secukinumab in plaque psoriasis
10.1056/nejmoa2102383 · ExternalCitation · doi-reference
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
10.1093/bjd/ljae062 · ExternalCitation · doi-reference
Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management
10.1111/bjd.17128 · ExternalCitation · doi-reference
Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients
10.1111/bjd.17403 · ExternalCitation · doi-reference
Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA
10.1111/ced.12841 · ExternalCitation · doi-reference
Variation of body regional responses to Ustekinumab and Secukinumab in psoriasis patients: a real-world retrospective study and literature review
10.1111/dth.15950 · ExternalCitation · doi-reference
Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies
10.1111/jdv.12106 · ExternalCitation · doi-reference
Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression
10.1111/jdv.14460 · ExternalCitation · doi-reference
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
10.1111/jdv.14878 · ExternalCitation · doi-reference
Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis
10.1111/jdv.14951 · ExternalCitation · doi-reference
Neuroimmune interactions in chronic itch of atopic dermatitis
10.1111/jdv.15973 · ExternalCitation · doi-reference
Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis
10.1136/annrheumdis-2021-220865 · ExternalCitation · doi-reference
Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis
10.1177/0091270008329556 · ExternalCitation · doi-reference
Effectiveness of IL-23 inhibitor Guselkumab in real-world Chinese patients with psoriasis during a 20-week period
10.2147/ptt.s312109 · ExternalCitation · doi-reference
The psychosocial burden of psoriasis
10.2165/00128071-200506060-00005 · ExternalCitation · doi-reference
Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents
10.35541/cjd.20220652 · ExternalCitation · doi-reference
Effect of Ixekizumab on patient reported outcomes and quality of life in patients with moderate-to-severe plaque psoriasis: 5-year results from the UNCOVER-1 and -2 studies
10.36849/jdd.5821 · ExternalCitation · doi-reference
Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis
10.4049/jimmunol.1800013 · ExternalCitation · doi-reference
